Racial representation in recent atopic dermatitis trials has largely been representative of the U.S. population. Black individuals should be represented more because of disease prevalence rates.

3. Department of Dermatology, University of Nebraska Medical Center, Omaha, USA 4. Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, USA * ...

More information on the KT-621 BroADen trial in AD will be available on www.clinicaltrials.gov. Atopic dermatitis (AD) is the most common form of eczema, a chronic inflammatory disease that causes the ...

What are your key takeaways from this study, and how do the results influence your perspective on long-term options for the treatment of atopic dermatitis? In your current practice, where does ...

A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on biologics, the patients with moderate-to-severe atopic dermatitis on Janus ...

The majority of patients with head and neck atopic dermatitis treated with tralokinumab experienced improvements in their Eczema Area and Severity Index scores. Tralokinumab yields nearly 90% disease ...

Credit: Ladanifer / Shutterstock. Atopic dermatitis (AD) is a widespread, chronic inflammatory skin condition that can affect patients of all ages and is the result of a complex interplay of ...

Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. China State Key Laboratory of ...

Knowing that we don't specifically have head-to-head data amongst our biologic therapies in the atopic dermatitis realm, I kind of like to let the clinical data do the talking, to help guide us.

The atopic dermatitis (AD) treatment landscape is witnessing intensified competition with several novel therapies nearing market entry. While biologics like dupilumab have already transformed care, ...